Modern management of uterine fibroids

Acta Obstetricia et Gynecologica Scandinavica

Volumn 87, Issue 8, 2008, Pages 812-823

  Levy, Barbara S ^a,b  

^a St Francis Hospital   (United States)

^b NONE   (United States)

Author keywords

Embolization; Fibroid; Leiomyomata; Occlusion; Uterine artery

Indexed keywords

ASOPRISNIL; ESTRADIOL; GESTAGEN; GONADORELIN AGONIST; LEUPRORELIN; MIFEPRISTONE; NORETHISTERONE; RALOXIFENE; TIBOLONE;

BLOATING; CANCER RECURRENCE; CANCER SURGERY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FERTILITY; FLATULENCE; HEADACHE; HEALTH CARE COST; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYSTERECTOMY; LIBIDO DISORDER; LONG TERM CARE; MASTALGIA; MYOMECTOMY; NAUSEA; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESERVATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; UTERINE ARTERY EMBOLIZATION; UTERUS MYOMA; VOMITING; WEAKNESS;

ANTINEOPLASTIC AGENTS; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; HYSTERECTOMY; LEIOMYOMA; REPRODUCTIVE CONTROL AGENTS; ULTRASONIC THERAPY; UTERINE NEOPLASMS;

EID: 49649084240     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340802146912     Document Type: Review

References (80)

1. Solomon LA, Schimp VL, Ali-Fehmi R, Diamond MP, Munkarah AR. Clinical update of smooth muscle tumors of the uterus. J Minim Invasive Gynecol. 2005;12:401-8.
2. Guarnaccia MM, Rein MS. Traditional surgical approaches to uterine fibroids: Abdominal myomectomy and hysterectomy. Clin Obstet Gynecol. 2001;44:385-400.
3. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. Am J Obstet Gynecol. 2003;188:100-7.
4. Frishman GN, Jurema MW. Myomas and myomectomy. J Minim Invasive Gynecol. 2005;12:443-56.
5. Martin Chaves EB, Brum IS, Stoll J, Capp E, Corleta HE. Insulin-like growth factor 1 receptor mRNA expression and autophosphorylation in human myometrium and leiomyoma. Gynecol Obstet Invest. 2004;57:210-3.
6. Arici A, Sozen I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril. 2000;73:1006-11.
7. Luo X, Ding L, Xu J, Chegini N. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology. 2005;146:1097-118.
8. Shikora SA, Niloff JM, Bistrian BR, Forse RA, Blackburn GL. Relationship between obesity and uterine leiomyomata. Nutrition. 1991;7:251-5.
9. Day Baird D, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology. 2003;14:247-50.
10. Wallach EE, Vlahos NF. Uterine myomas: An overview of development, clinical features, and management. Obstet Gynecol. 2004;104:393-406.
11. Somigliana E, Vercellini P, Daguati R, Pasin R, De GO, Crosignani PG. Fibroids and female reproduction: A critical analysis of the evidence. Hum Reprod Update. 2007;13:465-76.
12. Sheth S, Macura K. Sonography of the uterine myometrium: Myomas and beyond. Ultrasound Clin. 2007;2:267-95.
13. Lee DW, Ozminkowski RJ, Carls GS, Wang S, Gibson TB, Stewart EA. The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids. J Occup Environ Med. 2007;49:493-506.
14. Common AA, Mocarski EJ, Kolin A, Pron G, Soucie J. Therapeutic failure of uterine fibroid embolization caused by underlying leiomyosarcoma. J Vasc Interv Radiol. 2001;12:1449-52.
15. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol. 1994;83:414-8.
16. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101:243-50.
17. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: A randomized controlled trial. Obstet Gynecol. 2006;108:1381-7.
18. Wang J, Ohara N, Wang Z, Chen W, Morikawa A, Sasaki H, et al. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod. 2006;21:1869-77.
19. Chen W, Ohara N, Wang J, Xu Q, Liu J, Morikawa A, et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab. 2006;91:1296-304.
20. Sasaki H, Ohara N, Xu Q, Wang J, DeManno DA, Chwalisz K, et al. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab. 2007;92:616-23.
21. Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril. 2007;87:1399-412.
22. Williams AR, Critchley HO, Osei J, Ingamells S, Cameron IT, Han C, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod. 2007;22:1696-704.
23. Chillik C, Acosta A. The role of LHRH agonists and antagonists. Reprod Biomed Online. 2001;2:120-8.
24. Georgia Reproductive Specialists. Leiomyomas of the uterusfibroid tumors. Available at: http://www.ivf.com/fibroid.html (accessed March 10, 2008).
25. Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD, for the Leuprolide Study Group. Treatment of leiomyomata uteri with leuprolide acetate depot: A double-blind, placebo-controlled, multicenter study. Obstet Gynecol. 1991;77:720-5.
26. Chavez NF, Stewart EA. Medical treatment of uterine fibroids. Clin Obstet Gynecol. 2001;44:372-84.
27. Palomba S, Orio F Jr., Morelli M, Russo T, Pellicano M, Zupi E, et al. Raloxifene administration in premenopausal women with uterine leiomyomas: A pilot study. J Clin Endocrinol Metab. 2002;87:3603-8.
28. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol. 2002;99:229-34.
29. Farquhar CM, Harvey SA, Yu Y, Sadler L, Stewart AW. A prospective study of 3 years of outcomes after hysterectomy with and without oophorectomy. Am J Obstet Gynecol. 2006;194:711-7.
30. Meyers ER, Steege JF. Risk adjustment for complications of hysterectomy: Utility of routinely collected administrative data. Prim Care Update Ob Gyns. 1998;5:202-3.
31. Dembek CJ, Pelletier EM, Isaacson KB, Spies JB. Payer costs in patients undergoing uterine artery embolization, hysterectomy, or myomectomy for treatment of uterine fibroids. J Vasc Interv Radiol. 2007;18:1207-13.
32. Tulandi T, Kabli N. Update on management of uterine fibroid. Available at: http://www.obgyn.net/Frontiers_In_Reproductive_Medicine/ management_uterine_fibroid.asp (accessed February 29, 2008).
33. Seracchioli R, Rossi S, Govoni F, Rossi E, Venturoli S, Bulletti C, et al. Fertility and obstetric outcome after laparoscopic myomectomy of large myomata: A randomized comparison with abdominal myomectomy. Hum Reprod. 2000;15:2663-8.
34. Parker WH. Laparoscopic myomectomy and abdominal myomectomy. Clin Obstet Gynecol. 2006;49:789-97.
35. Kongnyuy EJ, Wiysonge CS. Interventions to reduce haemorrhage during myomectomy for fibroids. Cochrane Database Syst Rev. 2007;CD005355.
36. Dumousset E, Chabrot P, Rabischong B, Mazet N, Nasser S, Darcha C, et al. Preoperative uterine artery embolization (PUAE) before uterine fibroid myomectomy. Cardiov Intervent Radiol. 2008;31:514-20.
37. Doridot V, Dubuisson JB, Chapron C, Fauconnier A, Babaki-Fard K. Recurrence of leiomyomata after laparoscopic myomectomy. J Am Assoc Gynecol Laparosc. 2001;8:495-500.
38. Hanafi M. Predictors of leiomyoma recurrence after myomectomy. Obstet Gynecol. 2005;105:877-81.
39. Hurst BS, Matthews ML, Marshburn PB. Laparoscopic myomectomy for symptomatic uterine myomas. Fertil Steril. 2005;83:1-23.
40. Reproductive Science Center of the San Francisco Bay Area. Laparoscopic/hysteroscopic myomectomy. Available at: http://www.drgalen.com/ myomectomy.html (accessed February 29, 2008).
41. Goldman EL. Laparoscopic myomectomy may save $300/ case - Analysis Compares Costs to Open Procedure. Available at: http://findarticles.com/p/ articles/mi_m0CYD/is_4_37/ai_83530607 (accessed February 29, 2008).
42. Subramanian S, Clark MA, Isaacson K. Outcome and resource use associated with myomectomy. Obstet Gynecol. 2001;98:583-7.
43. Phillips DR, Nathanson HG, Milim SJ, Haselkorn JS. Laparoscopic leiomyoma coagulation. J Am Assoc Gynecol Laparosc. 1996;3:S39.
44. Zupi E, Piredda A, Marconi D, Townsend D, Exacoustos C, Arduini D, et al. Directed laparoscopic cryomyolysis: A possible alternative to myomectomy and/or hysterectomy for symptomatic leiomyomas. Am J Obstet Gynecol. 2004;190:639-43.
45. Zupi E, Marconi D, Sbracia M, Exacoustos C, Piredda A, Sorrenti G, et al. Directed laparoscopic cryomyolysis for symptomatic leiomyomata: One-year follow up. J Minim Invasive Gynecol. 2005;12:343-6.
46. Kroencke TJ, Scheurig C, Kluner C, Taupitz M, Schnorr J, Hamm B. Uterine fibroids: Contrast-enhanced MR angiography to predict ovarian artery supply - initial experience. Radiology. 2006;241:181-9.
47. Burbank F, Hutchins FL Jr. Uterine artery occlusion by embolization or surgery for the treatment of fibroids: A unifying hypothesis-transient uterine ischemia. J Am Assoc Gynecol Laparosc. 2000;7 Suppl 4:S1-S49.
48. Sharp HT. Assessment of new technology in the treatment of idiopathic menorrhagia and uterine leiomyomata. Obstet Gynecol. 2006;108:990-1003.
49. Myers ER, Goodwin S, Landow W, Mauro M, Peterson E, Pron G, et al. Prospective data collection of a new procedure by a specialty society: The FIBROID registry. Obstet Gynecol. 2005;106:44-51.
50. Spies JB, Myers ER, Worthington-Kirsch R, Mulgund J, Goodwin S, Mauro M. The FIBROID Registry: Symptom and quality-of-life status 1 year after therapy. Obstet Gynecol. 2005;106:1309-18.
51. Smith WJ, Upton E, Shuster EJ, Klein AJ, Schwartz ML. Patient satisfaction and disease specific quality of life after uterine artery embolization. Am J Obstet Gynecol. 2004;190:1697-703.
52. Spies JB, Warren EH, Mathias SD, Walsh SM, Roth AR, Pentecost MJ. Uterine fibroid embolization: Measurement of health-related quality of life before and after therapy. J Vasc Interv Radiol. 1999;10:1293-303.
53. Volkers NA, Hehenkamp WJ, Birnie E, Ankum WM, Reekers JA. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: 2 years' outcome from the randomized EMMY trial. Am J Obstet Gynecol. 2007;196:519.e1-519.e11.
54. Worthington-Kirsch R, Spies JB, Myers ER, Mulgund J, Mauro M, Pron G, et al. The Fibroid Registry for outcomes data (FIBROID) for uterine embolization: Short-term outcomes. Obstet Gynecol. 2005;106:52-9.
55. Spies JB, Spector A, Roth AR, Baker CM, Mauro L, Murphy-Skrynarz K. Complications after uterine artery embolization for leiomyomas. Obstet Gynecol. 2002;100:873-80.
56. Hehenkamp WJ, Volkers NA, Donderwinkel PF, de BS, Birnie E, Ankum WM, et al. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids (EMMY trial): peri- and postprocedural results from a randomized controlled trial. Am J Obstet Gynecol. 2005;193:1618-29.
57. Al-Fozan H, Tulandi T. Factors affecting early surgical intervention after uterine artery embolization. Obstet Gynecol Surv. 2002;57:810-5.
58. Chrisman HB, Saker MB, Ryu RK, Nemcek AA Jr., Gerbie MV, Milad MP, et al. The impact of uterine fibroid embolization on resumption of menses and ovarian function. J Vasc Interv Radiol. 2000;11:699-703.
59. American College of Obstetricians and Gynecologists. Uterine artery embolization. ACOG Committee Opinion No. 293. Obstet Gynecol. 2004;103:403-4.
60. Hehenkamp WJ, Volkers NA, Broekmans FJ, de Jong FH, Themmen AP, Birnie E, et al. Loss of ovarian reserve after uterine artery embolization: A randomized comparison with hysterectomy. Hum Reprod. 2007;22:1996-2005.
61. Walker WJ, McDowell SJ. Pregnancy after uterine artery embolization for leiomyomata: A series of 56 completed pregnancies. Am J Obstet Gynecol. 2006;195:1266-71.
62. National Institute for Health and Clinical Excellence. Heavy menstrual bleeding. Clinical guideline CG44. Available at: http://www.nice.org.uk/ guidance/CG44 (accessed July 24, 2007).
63. Lichtinger M, Hallson L, Calvo P, Adeboyejo G. Laparoscopic uterine artery occlusion for symptomatic leiomyomas. J Am Assoc Gynecol Laparosc. 2002;9:191-8.
64. Holub Z, Jabor A, Lukac J, Kliment L, Urbanek S. Midterm follow-up study of laparoscopic dissection of uterine vessels for surgical treatment of symptomatic fibroids. Surg Endosc. 2004;18:1349-53.
65. Hald K, Klow NE, Qvigstad E, Istre O. Laparoscopic occlusion compared with embolization of uterine vessels: A randomized controlled trial. Obstet Gynecol. 2007;109:20-7.
66. Hald K, Langebrekke A, Klow NE, Noreng HJ, Berge AB, Istre O. Laparoscopic occlusion of uterine vessels for the treatment of symptomatic fibroids: Initial experience and comparison to uterine artery embolization. Am J Obstet Gynecol. 2004;190:37-43.
67. Holub Z, Eim J, Jabor A, Hendl A, Lukac J, Kliment L. Complications and myoma recurrence after laparoscopic uterine artery occlusion for symptomatic myomas. J Obstet Gynaecol Res. 2006;32:55-62.
68. Fibroid FAQs: Guided FUS Procedure, Uterine Cramping, Treatment Descriptions. What types of fibroids can be treated with the ExAblate 2000? Available at: http://www.uterinefibroids.org/faq.html#8 (accessed February 27, 2008).
69. Stewart EA, Gedroyc WM, Tempany CM, Quade BJ, Inbar Y, Ehrenstein T, et al. Focused ultrasound treatment of uterine fibroid tumors: Safety and feasibility of a noninvasive thermoablative technique. Am J Obstet Gynecol. 2003;189:48-54.
70. Stewart EA, Rabinovici J, Tempany CM, Inbar Y, Regan L, Gostout B, et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril. 2006;85:22-9.
71. Dickner SK, Cooper JM, Diaz D. A nonincisional, Doppler-guided transvaginal approach to uterine artery identification and control of uterine perfusion. J Am Assoc Gynecol Laparosc. 2004;11:55-8.
72. Lichtinger M, Herbert S, Memmolo A. Temporary, transvaginal occlusion of the uterine arteries: A feasibility and safety study. J Minim Invasive Gynecol. 2005;12:40-2.
73. Istre O, Hald K, Qvigstad E. Multiple myomas treated with a temporary, noninvasive, Doppler-directed, transvaginal uterine artery clamp. J Am Assoc Gynecol Laparosc. 2004;11:273-6.
74. Vilos GA, Vilos EC, Romano W, Abu-Rafea B. Temporary uterine artery occlusion for treatment of menorrhagia and uterine fibroids using an incisionless Doppler-guided transvaginal clamp: Case report. Hum Reprod. 2006;21:269-71.
75. Vilos GA, Lichtinger M. Transvaginal Doppler-guided uterine artery occlusion for the management of leiomyomata uteri: Initial pilot study results. J Minim Invasive Gynecol. 2007;14:S104.
76. Law P, Regan L. Interstitial thermo-ablation under MRI guidance for the treatment of fibroids. Curr Opin Obstet Gynecol. 2000;12:277-82.
77. Luo X, Shen Y, Song WX, Chen PW, Xie XM, Wang XY. Pathologic evaluation of uterine leiomyoma treated with radiofrequency ablation. Int J Gynaecol Obstet. 2007;99:9-13.
78. Bergamini V, Ghezzi F, Cromi A, Bellini G, Zanconato G, Scarperi S, et al. Laparoscopic radiofrequency thermal ablation: A new approach to symptomatic uterine myomas. Am J Obstet Gynecol. 2005;192:768-73.
79. Ghezzi F, Cromi A, Bergamini V, Scarperi S, Bolis P, Franchi M. Midterm outcome of radiofrequency thermal ablation for symptomatic uterine myomas. Surg Endosc. In press.
80. Kim HS, Tsai J, Jacobs MA, Kamel IR. Percutaneous image-guided radiofrequency thermal ablation for large symptomatic uterine leiomyomata after uterine artery embolization: A feasibility and safety study. J Vasc Interv Radiol. 2007;18:41-8.